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Editorial
Aortic valve-in-valve and hemodynamic outcomes: where are we?
Implante aórtico valve-in-valve e resultados hemodinâmicos: onde nós estamos?
The importance of valve-in-valve (VIV) has grown considerably 
over the last decade. Considering the evolving demographic profile of 
the Western world, this should come as no surprise. A few decades 
ago, while it was known that bioprosthetic valves had limited durabil-
ity, surgeons everywhere were less concerned about what would hap-
pen when the devices became dysfunctional because most patients 
“failed” before their valves did.1,2 However, with the massive increase 
in life expectancy3 and a greater utilization of bioprostheses,4 it be-
came prudent to actively find alternatives for these patients. 
In this issue of the Revista Brasileira de Cardiologia Invasiva, 
Meneguz-Moreno et al. present a series of seven cases of aortic 
VIV from two major tertiary hospitals. The patients were all male 
with a mean age of 72.6 ± 10 years and had elevated risk scores 
(Society of Thoracic Surgeons - STS 9.6 ± 10.5% and logistic Euro-
SCORE 22.7 ± 14.7%). Mixed failure was the most common type of 
failure in the cohort (three cases, 42.8%); stenosis and regurgita-
tion were equally common (two cases each, 28.6%). Their experi-
ence was divided into two CoreValve (Medtronic, Minneapolis, 
USA) and five SAPIEN XT (Edwards Lifesciences, Irvine, USA) cas-
es. Mean gradients post-procedure, albeit reduced, still remained 
worse than the Valve Academic Research Consortium (VARC)-2 
cut-off (20.9 ± 5.9 mmHg). However, there was a clear improve-
ment in the symptom status of the patients. Operators obtained 
successful results and further demonstrated the reproducibility 
and safety of VIV in diverse clinical settings.
VIV consists in the insertion of a transcatheter heart valve (THV) 
into a failed bioprosthetic valve.5 The gold standard is still the con-
ventional surgical replacement of the failed valve.6 Surgical valves 
have proven long-term durability and outcomes,2,7 and more evi-
dence is needed to employ THV as the first therapeutic choice. Min-
imally invasive procedures certainly draw the attention of patients 
for obvious reasons. Replacing a valve without the risks of open-
heart surgery, reduced discharge times, conscious sedation, and less 
post-operative pain is understandably attractive. However, physi-
cians must be critical, judicious, and fully understand the shortcom-
ings of VIV. The Valve-in-Valve International Data (VIVID) Registry, 
founded in 2010, intends to provide scientific insight on both the 
advantages and disadvantages of the procedure.5
A key problem faced by Meneguz-Moreno et al. was the elevated 
post-operative mean gradient in three out of seven cases of the se-
ries. Elevated post-procedural gradients are not a new concern. In 
the seminal 2012 VIVID analysis published in Circulation,5 as well 
as in the 2014 Journal of the American Medical Association land-
mark paper,8 the high incidence of elevated post-procedure gradi-
ents (≥ 20 mmHg by VARC-2 criteria) was noted as one of three 
unresolved problems in VIV.
Operators have good reasons to consider gradients as a poten-
tial enemy. Elevated post-procedural gradients are intrinsically as-
sociated with prosthesis-patient mismatch.8 A large meta-analysis 
identified an association between moderate and severe prosthe-
sis-patient mismatch with worse outcomes.9,10 Some evidence also 
suggests that elevated gradients may further reduce leaflet dura-
bility, allowing for increased device degeneration,11 demanding 
earlier replacement.
We previously reported that the average mean gradient in the 
VIVID Registry was 15.8 ± 8.9 mmHg.8 However, transcatheter aortic 
valve replacement (TAVR) procedures in native valves have relatively 
low post-procedural mean gradients, in the range of 5 to 10 mmHg.12 
It could then be concluded that THV itself is not, on its own, respon-
sible for this phenomenon. The accepted current explanation for the 
high incidence involves a combination of predictors: baseline surgi-
cal valve stenosis and type of THV.13 
While biological tissues, such as the aortic root, are flexible, sur-
gical valve rings are structurally rigid. As a consequence, THV does 
not expand the surgical valve with it. Conversely, a rigid surgical 
valve may not allow full expansion of the THV. This is compounded 
by the mechanism of failure encountered in the surgical device. A 
primarily stenotic device has less malleable leaflets that may also 
impair THV expansion. A regurgitant one, on the other hand, is more 
pliable and would not demonstrate the issue in the same magnitude. 
Expansion of the THV is only important if it affects the func-
tional area of the leaflets. This is the fundamental rationale behind 
the status of the THV model as a predictor of elevated mean gradi-
ents. THV are not built equally. The leaflet area may be built at the 
level of the aortic (or, in our case, surgical valve) annulus, which 
would make the device intraannular, or it can be assembled above 
the annulus, hence supraannular.14 Examples of the former are the 
SAPIEN XT and the Portico (St. Jude Medical, St. Paul, USA) valves. 
The most important of the latter is the CoreValve. A supraannular 
device is less affected by the rigidity of the surgical valve. Better 
expansion of the device, with improved leaflet coaptation, would 
be expected in a supraannular position. 
A natural next-step would be to involve THV positioning in this 
discussion. Theoretically, if an operator positions an intra-annular 
device high enough, it would eventually be “supra-annularified”. In 
the same way, implanting a supra-annular device too low could po-
tentially constrict the functional area of the THV. Obtaining greater 
insight on the importance of positioning was the objective of the 
currently in-press in vivo and in vitro depth of implantation analyses 
of the Registry.13 We found, in the in vitro section, that higher im-
plantation is associated with lower gradients and larger effective 
orifice area in SAPIEN XT, CoreValve, and Portico valves.
This was confirmed by a 292-patient analysis, which identified 
high positioning as the most important protector against high gradi-
ents, followed by CoreValve use. Baseline stenosis was, as expected, 
identified as a predictor of higher gradients. Optimal cutoffs for po-
sitioning were identified: zero to 5 mm depth for CoreValve cases 
and zero to 10% of frame length (~2 mm) for SAPIEN XT cases.13 Ad-
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vances in the field are needed. While high positioning provides a 
clinically feasible manner of preventing poor hemodynamics, newer 
surgical valves could further improve VIV hemodynamic outcomes. 
Improvements in surgical valve technology, aiming for future VIV, 
are crucial: proper fluoroscopic markings, expandable annuli, and 
large internal diameters are features that could potentially improve 
procedural quality. 
In conclusion, VIV is a promising, less invasive approach that 
may offer life-saving possibilities for many patients. There are still 
procedural challenges that may impair desired outcomes. Howev-
er, there is a rich amount of experience in the field that allows op-
erators to perform the procedure safely. We encourage newcomers 
into the field to learn about the procedure and enrich the present 
state of knowledge. 
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